Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia

Published:2023-06-27 Issue:1 Volume:26 Page:278-287
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Ramos Elbal Eduardo,Fuster Jose Luis,Campillo José A.,Galera Ana María,Cortés Mar Bermúdez,Llinares María Esther,Jiménez Irene,Plaza Mercedes,Martínez Banaclocha Helios,Galián José Antonio,Blanquer Blanquer Miguel,Martínez Sánchez María Victoria,Muro Manuel,Minguela Alfredo^ORCID

Funder

Asociación Pablo Ugarte

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12094-023-03251-0.pdf

Reference25 articles.

1. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. New Eng J Med. 2015;373(16):1541–52.

2. Pui CH, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938–48.

3. Schrappe M. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukemia. Radiat Prot Dosim. 2008;132(2):130–3.

4. Raff T, Gökbuget N, Lüschen S, Reutzel R, Ritgen M, Irmer S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109(3):910–5.

5. van Dongen JJM, van der Velden VHJ, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009.